Active	Status	Sponsor type	Region	Phase	Filter
13 Active 2 Inactive 15 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Boeve, Bradley F
NCT04993755 / 2021-002251-11: A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD	Active, not recruiting	2a	42	Europe, US	TPN-101, 400 mg/day, Placebo	Transposon Therapeutics, Inc., Transposon Therapeutics, Inc	Amyotrophic Lateral Sclerosis, Frontotemporal Dementia	09/23	09/23
SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects with Mild to Moderate Dementia with Lewy Bodies	Completed	2	130	US	CT1812	Cognition Therapeutics, National Institute on Aging (NIA)	Dementia with Lewy Bodies	11/24	11/24
EIP21-NFD-504, NCT05869669: RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies	Active, not recruiting	2	160	Europe, US	Neflamapimod, VX-745, Placebo	EIP Pharma Inc, National Institute on Aging (NIA), Worldwide Clinical Trials, CervoMed, Inc	Dementia With Lewy Bodies	08/24	03/25
Manthei, Marissa
SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects with Mild to Moderate Dementia with Lewy Bodies	Completed	2	130	US	CT1812	Cognition Therapeutics, National Institute on Aging (NIA)	Dementia with Lewy Bodies	11/24	11/24
EIP21-NFD-504, NCT05869669: RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies	Active, not recruiting	2	160	Europe, US	Neflamapimod, VX-745, Placebo	EIP Pharma Inc, National Institute on Aging (NIA), Worldwide Clinical Trials, CervoMed, Inc	Dementia With Lewy Bodies	08/24	03/25